Examining how gadolinium contrast agents are excreted in urine after MRI
Kinetics of Urinary Excretion of Gadolinium Contrast Agents Used in MRI Examinations
This study is testing how well patients can get rid of gadolinium contrast agents in their urine after an MRI to help find better ways to manage waste from these substances.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Régional Metz-Thionville Academic / other |
| Locations | 1 site (Metz, Grand Est) |
| Trial ID | NCT06191731 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs) used in MRI examinations. Patients who have been prescribed an MRI with Gd-CAs will provide blood and urine samples before and after the injection of the contrast agent. The goal is to assess the feasibility of recovering gadolinium from urine to prevent environmental contamination, as current wastewater treatment processes do not eliminate these compounds effectively. This research could lead to improved protocols for managing gadolinium waste in medical settings.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have a prescription for an MRI with gadolinium-based contrast agents.
Not a fit: Patients with known allergies to gadolinium contrast agents, severe renal impairment, or those unable to urinate independently may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better environmental management of gadolinium contrast agents used in MRI, reducing their impact on freshwater ecosystems.
How similar studies have performed: While the approach of recovering gadolinium from urine is novel, previous studies have highlighted the environmental concerns associated with gadolinium contrast agents, indicating a need for such research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients: * over 18 years of age * with a prescription for MRI with gadolinium-based contrast agents (Gd-CAs) injection validated by a radiologist * affiliated with a health insurance plan * have signed an informed consent form Exclusion Criteria: * Patients: * with known allergy to gadolinium-based contrast agents (Gd-CAs) * with known severe renal impairment (GFR \< 30 mL/min) * on dialysis * with urinary incontinence * with an ongoing urinary tract infection * under hydric or hydrosodic restriction * unable to urinate independently * Protected persons (under guardianship, curatorship or safeguard of justice) * Pregnant or breast-feeding women
Where this trial is running
Metz, Grand Est
- CHR Metz-Thionville/Hopital de Mercy — Metz, Grand Est, France (Recruiting)
Study contacts
- Principal investigator: Rémi DUPRES, MD — CHR Metz Thionville Hopital Mercy
- Study coordinator: Arpiné EL NAR, PhD
- Email: projet-recherche-clinique@chr-metz-thionville.fr
- Phone: 0033387557766
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.